The present work focused on evaluating the feasibility of fused deposition modeling (FDM) in the development of a dosage form containing Timapiprant (TMP), also known as CHF6532, which is a novel active molecule indicated in the potential treatment of eosinophilic asthma upon oral administration. The resulting product could be an alternative, with potential towards personalization, of immediate release (IR) tablets used in the clinical studies. Formulations based on different polymeric carriers were screened, leading to the identification of a polyvinyl alcohol-based one, which turned out acceptable for versatility in terms of active ingredient content, printability and dissolution performance (i.e. capability to meet the dissolution specification set, envisaging >80% of the drug dissolved within 30 min). Following an in-depth evaluation on the influence of TMP solid state and of the voids volume resulting from printing on dissolution, few prototypes with shapes especially devised for therapy customization were successfully printed and were compliant with the dissolution specification set.
Investigation on the use of fused deposition modeling for the production of IR dosage forms containing Timapiprant / M. Uboldi, A. Chiappa, M. Pertile, A. Piazza, S. Tagliabue, A. Foppoli, L. Palugan, A. Gazzaniga, L. Zema, A. Melocchi. - In: INTERNATIONAL JOURNAL OF PHARMACEUTICS. X. - ISSN 2590-1567. - 5:(2023), pp. 100152.1-100152.14. [10.1016/j.ijpx.2022.100152]
Investigation on the use of fused deposition modeling for the production of IR dosage forms containing Timapiprant
M. UboldiPrimo
;A. Foppoli;L. Palugan
;A. Gazzaniga;L. ZemaPenultimo
;A. MelocchiUltimo
2023
Abstract
The present work focused on evaluating the feasibility of fused deposition modeling (FDM) in the development of a dosage form containing Timapiprant (TMP), also known as CHF6532, which is a novel active molecule indicated in the potential treatment of eosinophilic asthma upon oral administration. The resulting product could be an alternative, with potential towards personalization, of immediate release (IR) tablets used in the clinical studies. Formulations based on different polymeric carriers were screened, leading to the identification of a polyvinyl alcohol-based one, which turned out acceptable for versatility in terms of active ingredient content, printability and dissolution performance (i.e. capability to meet the dissolution specification set, envisaging >80% of the drug dissolved within 30 min). Following an in-depth evaluation on the influence of TMP solid state and of the voids volume resulting from printing on dissolution, few prototypes with shapes especially devised for therapy customization were successfully printed and were compliant with the dissolution specification set.File | Dimensione | Formato | |
---|---|---|---|
1-s2.0-S2590156722000433-main.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
8.39 MB
Formato
Adobe PDF
|
8.39 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.